MarketPulse

regulatory disclosure

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Class Action Lawsuit Filed Against Aquestive Therapeutics Over Alleged Securities Violations

Rosen Law Firm filed class action against Aquestive Therapeutics alleging false statements about product development and regulatory matters. Eligible investors should act before deadline.
ENPHAQSTNKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Orange Updates Share Count and Voting Rights; Treasury Holdings Signal Capital Strategy Shift

Orange reports 2.66 billion shares outstanding and 3.18 billion voting rights as of February 28, 2026, with treasury holdings increasing 20.6% in one month, signaling active buyback strategy.
ORANYvoting rightstreasury shares
GlobeNewswire Inc.GlobeNewswire Inc.··Globenewswire

Renk Group Executive Transaction Signals Leadership Activity in Defense Sector Supplier

Renk Group AG files routine executive transaction notification involving manager Anja Mänz-Siebje, demonstrating compliance with European securities regulations.
RKGRYacquisitionregulatory disclosure
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Renk Group Executive Anja Mänz-Siebje Executes Stock Acquisition

Renk Group AG executive Anja Mänz-Siebje completes insider stock transaction, subject to regulatory disclosure requirements.
RKGRYacquisitionregulatory disclosure
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi Files 2025 Annual Financial Disclosures with U.S. and French Regulators

Sanofi files 2025 annual financial disclosures with U.S. SEC and French AMF regulators, completing required reporting obligations for the international pharmaceutical company.
SNYForm 20-FSEC filing
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Pharmaceuticals Faces Securities Class Action Over Manufacturing and Regulatory Claims

Rosen Law Firm sues Inovio Pharmaceuticals for allegedly making false statements about manufacturing capabilities and regulatory timelines, causing investor losses through inflated stock prices.
INOsecurities class actionFDA approval